{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:58:41Z","timestamp":1767859121328,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,4]],"date-time":"2010-01-04T00:00:00Z","timestamp":1262563200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cases Journal"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1757-1626-3-4","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T07:16:20Z","timestamp":1262675780000},"source":"Crossref","is-referenced-by-count":7,"title":["T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report"],"prefix":"10.1186","volume":"3","author":[{"given":"Manish","family":"Singhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Raina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasenjit","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,4]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.1985.3.12.1640","volume":"3","author":"B Fisher","year":"1985","unstructured":"Fisher B, Rockette H, Fisher ER, Wickerham DL, Redmond C, Brown A: Leukemia in Breast Cancer Patients Following Adjuvant Chemotherapy or Postoperative Radiation: The NSABP Experience. J Clin Oncol. 1985, 3: 1640-1658.","journal-title":"J Clin Oncol"},{"key":"1490_CR2","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","volume":"326","author":"RE Curtis","year":"1992","unstructured":"Curtis RE, Boice JD, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992, 326: 1745-1751.","journal-title":"N Engl J Med"},{"key":"1490_CR3","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.1996.14.10.2722","volume":"14","author":"E Diamandidou","year":"1996","unstructured":"Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996, 14: 2722-2730.","journal-title":"J Clin Oncol"},{"key":"1490_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3816\/CBC.2003.n.032","volume":"4","author":"RE Smith","year":"2003","unstructured":"Smith RE: Risk for the development of treatment-related acute myelocytic leukemia andmyelodysplastic syndrome among patients withbreast cancer: Review of the literature and theNational Surgical Adjuvant Breast and Bowel Projectexperience. Clin Breast Cancer. 2003, 4: 273-279. 10.3816\/CBC.2003.n.032.","journal-title":"Clin Breast Cancer"},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1200\/JCO.2005.05.029","volume":"23","author":"C Praga","year":"2005","unstructured":"Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D: Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005, 23: 4179-4191. 10.1200\/JCO.2005.05.029.","journal-title":"J Clin Oncol"},{"key":"1490_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1200\/JCO.2006.05.9048","volume":"25","author":"MC Le Deley","year":"2007","unstructured":"Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C: Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007, 25: 292-300. 10.1200\/JCO.2006.05.9048.","journal-title":"J Clin Oncol"},{"key":"1490_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1200\/JCO.2008.17.1033","volume":"27","author":"S Chakraborty","year":"2009","unstructured":"Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, Forman S, Bhatia S, Bhatia R: Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol. 2009, 27: 791-798. 10.1200\/JCO.2008.17.1033.","journal-title":"J Clin Oncol"},{"key":"1490_CR8","first-page":"RA69","volume":"13","author":"R Tadeusz","year":"2009","unstructured":"Tadeusz R, Pawe\u0142 R: Current treatment options in prolymphocytic leukemia. Med Sci Monit. 2009, 13: RA69-80.","journal-title":"Med Sci Monit"},{"key":"1490_CR9","first-page":"152","volume":"7","author":"B Friedenson","year":"2007","unstructured":"Friedenson B: The BRCA1\/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BioMed Central Cancer. 2007, 7: 152-163.","journal-title":"BioMed Central Cancer"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden CE, Matutes E, Cazin B, Tj\u00f8nnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D: High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001, 98: 1721-1726. 10.1182\/blood.V98.6.1721.","journal-title":"Blood"},{"key":"1490_CR11","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","volume":"12","author":"J Mercieca","year":"1994","unstructured":"Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D: The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994, 12: 2588-2593.","journal-title":"J Clin Oncol"}],"container-title":["Cases Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1757-1626-3-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1757-1626-3-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1757-1626-3-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T11:14:34Z","timestamp":1548242074000},"score":1,"resource":{"primary":{"URL":"https:\/\/casesjournal.biomedcentral.com\/articles\/10.1186\/1757-1626-3-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,4]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/1757-1626-3-4","relation":{},"ISSN":["1757-1626"],"issn-type":[{"value":"1757-1626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,4]]},"article-number":"4"}}